WEX Pharmaceuticals Inc. - Strategic SWOT Analysis Review

Date: January 25, 2016
Pages: 23
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: WCEBFCDAA7BEN
Leaflet:

Download PDF Leaflet

WEX Pharmaceuticals Inc. - Strategic SWOT Analysis Review
WEX Pharmaceuticals Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

WEX Pharmaceuticals Inc. (WEX), is a clinical stage biotechnology company that focuses on the discovery, development, manufacture and commercialization of innovative drugs for pain management. The company develops a new class of non-opioid analgesics utilizing its proprietary platform technology Halneuron (Tetrodotoxin or TTX). Halneuron is a non-peptide neurotoxin, non-addictive alternative to opioids, and a sodium channel blocker. WEX’s clinical candidates include TEC-006 and TTX-CINP-201.Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

WEX Pharmaceuticals Inc. - Key Facts
WEX Pharmaceuticals Inc. - Key Employees
WEX Pharmaceuticals Inc. - Major Products and Services
WEX Pharmaceuticals Inc. - Pharmaceutical Pipeline Products Data
WEX Pharmaceuticals Inc., Pipeline Products by Therapy Area
WEX Pharmaceuticals Inc., Pipeline Products by Development Phase
WEX Pharmaceuticals Inc. - History
WEX Pharmaceuticals Inc. - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

WEX Pharmaceuticals Inc. - Business Description
WEX Pharmaceuticals Inc. - SWOT Analysis
SWOT Analysis - Overview
WEX Pharmaceuticals Inc. - Strengths
Strength - Proprietary Technology Platform - Halneuron
Strength - Synergy from CK Life Sciences
WEX Pharmaceuticals Inc. - Weaknesses
Weakness - Lack of Marketed Products
WEX Pharmaceuticals Inc. - Opportunities
Opportunity - Rising Aged Population
Opportunity - Increase Growth Potential for Pain Medications
Opportunity - Product Pipeline
WEX Pharmaceuticals Inc. - Threats
Threat - Uncertain R&D Outcomes
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Competitive Pressures
WEX Pharmaceuticals Inc. - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

WEX Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
WEX Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
WEX Pharmaceuticals Inc., Recent Deals Summary

SECTION 4 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

WEX Pharmaceuticals Inc., Key Facts
WEX Pharmaceuticals Inc., Key Employees
WEX Pharmaceuticals Inc., Major Products and Services
WEX Pharmaceuticals Inc., Number of Pipeline Products by Therapy Area
WEX Pharmaceuticals Inc., Number of Pipeline Products by Development Stage
WEX Pharmaceuticals Inc., Pipeline Products By Therapy Area and Development Phase
WEX Pharmaceuticals Inc., History
WEX Pharmaceuticals Inc., Key Competitors
WEX Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
WEX Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
WEX Pharmaceuticals Inc., Recent Deals Summary

LIST OF FIGURES

WEX Pharmaceuticals Inc., Pipeline Products by Therapy Area
WEX Pharmaceuticals Inc., Pipeline Products by Development Phase
WEX Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
WEX Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

WEX Pharmaceuticals Inc. - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: